SPAS(SH:603168) Ge Long Hui A P P·2026-01-15 08:00Core Viewpoint - The company, Zhejiang Shapuaisi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the supplementary application of Diflunisal tablets, indicating a significant advancement in its product portfolio [1]. Group 1: Product Approval - The company has obtained the approval notice for Diflunisal tablets, with notification numbers 2026B00097 and 2026B00098 [1]. - Diflunisal tablets have passed the consistency evaluation of generic drug quality and efficacy, which is crucial for market entry [1]. Group 2: Indications and Applications - The approved Diflunisal tablets are indicated for rheumatoid arthritis, osteoarthritis, and various mild to moderate pain conditions, expanding the therapeutic options available [1]. Group 3: R&D Investment - As of the date of the announcement, the total research and development investment for the Diflunisal tablet project amounts to approximately 7.1492 million RMB [1].